.Attributes Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin caused improved progression-free as well as general survival, causing FDA commendation as well as a brand new therapy alternative for clients.